Modulation of NF-κB/miR-21/PTEN Pathway Sensitizes Non-Small Cell Lung Cancer to Cisplatin

• DOI: 10.1371/journal.pone.0121547
• Publication Date: 2015-03-23T18:45:53Z
• Authors: Zhenhua Yang; Surong Fang; Yicheng Di; Weiwei Ying; Yan Tan; Wei Gu
• Keywords: Viability assay

Background Platinum-based chemotherapy is a standard strategy for non-small cell lung cancer (NSCLC), while chemoresistance remains major therapeutic challenge in current clinical practice. Our present study was aimed to determine whether inhibition of the NF-κB/miR-21/PTEN pathway could increase sensitivity NSCLC cisplatin. Methods The expression miR-21 tissues determined using situ hybridization. Next, effect on A549 cells cisplatin vitro. Whether regulated PTEN assessed by luciferase assay. Furthermore, NF-κB targeted its binding elements gene promoter and ChIP Finally, we measured viability apoptosis under treatment when inhibited. Results An elevated level observed related short survival time. Exogenous promoted exposed cisplatin, reverse this process. RNA protein levels were significantly decreased exogenous miR-21, 3′-untranslated region shown be target miR-21. element promoter, finding that verified Hence, silencing protects against via decreasing expression. Conclusion Modulation showed may sensitivity.